NS830-M
GFAP ELISA Kit
Sinônimo(s):
GFAP, GFAP, Glial Fibrillary Acidic Protein ELISA, Glial fibrillary acidic protein
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Código UNSPSC:
12161503
eCl@ss:
32161000
Produtos recomendados
reatividade de espécies
rat, mouse, human
fabricante/nome comercial
Chemicon®
assay range
sensitivity: 1.5 ng/mL
standard curve range: 1.5-100 ng/mL
técnica(s)
ELISA: suitable
nº de adesão NCBI
nº de adesão UniProt
método de detecção
colorimetric
Informações sobre genes
human ... GFAP(2670)
Descrição geral
Background
Glial Fibrillary Acidic Protein (GFAP) is a class-III intermediate filament uniquely and ubiquitously expressed as part of the structural network in astrocytic glial cells. This specific expression makes GFAP ideal as a broad astrocytic marker in vertebrates. Astrocytes play a variety of key roles in supporting, guiding, nurturing, and signaling neuronal architecture and activity in a highly interdependent manner. Current understanding of CNS structure suggests that there are at least as many glial cells as the estimated 100 billion neurons, but perhaps upwards of 100 times more. Thus,
the health of both neurons and astrocytes is often affected in disease and trauma. GFAP is proving to be a useful biomarker in the detection of neural degeneration. Although defects in GFAP have been reported to cause certain rare conditions, such as Alexander’s disease (Brenner et al., 2001), the observed interconnected physiology of neuronal and glial cells has enabled the use of GFAP as a neurodegeneration detection gauge. This relationship is being exploited by researchers and clinicians measuring a variety of neurological issues from cancer to trauma. GFAP has been used as a biomarker in the early detection of chemically induced cancer (Capo et al., 1997) and classical glioblastomas (Jung et al., 2007). Elevated levels of GFAP have been reported in traumatic brain injury (TBI) and appear to directly correlate with the severity of injury and brain tissue oxygenation in combat casualty care research (CCR, 2008) as well as civilian accidents (Mondello et al., 2010). GFAP has also been identified as a good biomarker in studies of toxin induced acute brain injury (Liao et al., 2008), in differentiation of hemorrhagic vs. ischemic strokes (Foerch et al., 2006), as well as in cardiac arrest (Kaneko et al., 2009). Millipore now offers an ELISA assay for sensitive measurement of GFAP protein in tissue homogenates and biological fluids (serum, plasma, CSF, and serum free media) from human, mouse, and rat.
Principals of Procedure
This assay is a Sandwich ELISA based sequentially on: 1) capture of soluble GFAP protein to the wells of a microtiter plate coated by a pre-titered amount of anti-GFAP monoclonal antibody; 2) removal of unbound material by washing; 3) binding of biotinylated anti-GFAP monoclonal antibody to
the previously captured GFAP protein; 4) removal of unbound material by washing; 5) binding of streptavidin conjugated horseradish peroxidase to the biotinylated antibodies; 6) removal of excess or unbound enzyme conjugates by washing; and 7) quantification of immobilized antibody-enzyme
complexes by monitoring horseradish peroxidase activity in the presence of the substrate 3,3’,5,5’-tetramethylbenzidine (TMB). Enzyme activity is measured spectrophotometrically by recording absorbance readings at 450 nm. Increases in absorbency are directly proportional to the amount of
GFAP protein captured from the sample. Therefore the protein concentration of unknowns can be derived by interpolation using a standard curve generated in the same assay with reference standards of known concentrations of GFAP.
Glial Fibrillary Acidic Protein (GFAP) is a class-III intermediate filament uniquely and ubiquitously expressed as part of the structural network in astrocytic glial cells. This specific expression makes GFAP ideal as a broad astrocytic marker in vertebrates. Astrocytes play a variety of key roles in supporting, guiding, nurturing, and signaling neuronal architecture and activity in a highly interdependent manner. Current understanding of CNS structure suggests that there are at least as many glial cells as the estimated 100 billion neurons, but perhaps upwards of 100 times more. Thus,
the health of both neurons and astrocytes is often affected in disease and trauma. GFAP is proving to be a useful biomarker in the detection of neural degeneration. Although defects in GFAP have been reported to cause certain rare conditions, such as Alexander’s disease (Brenner et al., 2001), the observed interconnected physiology of neuronal and glial cells has enabled the use of GFAP as a neurodegeneration detection gauge. This relationship is being exploited by researchers and clinicians measuring a variety of neurological issues from cancer to trauma. GFAP has been used as a biomarker in the early detection of chemically induced cancer (Capo et al., 1997) and classical glioblastomas (Jung et al., 2007). Elevated levels of GFAP have been reported in traumatic brain injury (TBI) and appear to directly correlate with the severity of injury and brain tissue oxygenation in combat casualty care research (CCR, 2008) as well as civilian accidents (Mondello et al., 2010). GFAP has also been identified as a good biomarker in studies of toxin induced acute brain injury (Liao et al., 2008), in differentiation of hemorrhagic vs. ischemic strokes (Foerch et al., 2006), as well as in cardiac arrest (Kaneko et al., 2009). Millipore now offers an ELISA assay for sensitive measurement of GFAP protein in tissue homogenates and biological fluids (serum, plasma, CSF, and serum free media) from human, mouse, and rat.
Principals of Procedure
This assay is a Sandwich ELISA based sequentially on: 1) capture of soluble GFAP protein to the wells of a microtiter plate coated by a pre-titered amount of anti-GFAP monoclonal antibody; 2) removal of unbound material by washing; 3) binding of biotinylated anti-GFAP monoclonal antibody to
the previously captured GFAP protein; 4) removal of unbound material by washing; 5) binding of streptavidin conjugated horseradish peroxidase to the biotinylated antibodies; 6) removal of excess or unbound enzyme conjugates by washing; and 7) quantification of immobilized antibody-enzyme
complexes by monitoring horseradish peroxidase activity in the presence of the substrate 3,3’,5,5’-tetramethylbenzidine (TMB). Enzyme activity is measured spectrophotometrically by recording absorbance readings at 450 nm. Increases in absorbency are directly proportional to the amount of
GFAP protein captured from the sample. Therefore the protein concentration of unknowns can be derived by interpolation using a standard curve generated in the same assay with reference standards of known concentrations of GFAP.
Aplicação
Research Category
Neuroscience
Neuroscience
Used to detect/quantify: GFAP
Embalagem
96 wells
Componentes
96-Well Anti-GFAP Coated Plate (CS206352): 1 Plate
1X Assay Buffer (CS206357): 40 mL
10X Wash Buffer (CS206360): 50 mL
GFAP Protein Standard (CS206361): 1 Vial
GFAP Quality Control #1 (CS206351): 1 Vial
GFAP Quality Control #2 (CS206475): 1 Vial
Biotinylated Anti-GFAP Detection Antibody (CS206356): 12 mL
Enzyme Solution (CS206358): 12 mL
TMB Solution (CS202682): 10 mL
Stop Solution (60193): 12 mL
Plate Sealers (CS200443): 10 Sheets
1X Assay Buffer (CS206357): 40 mL
10X Wash Buffer (CS206360): 50 mL
GFAP Protein Standard (CS206361): 1 Vial
GFAP Quality Control #1 (CS206351): 1 Vial
GFAP Quality Control #2 (CS206475): 1 Vial
Biotinylated Anti-GFAP Detection Antibody (CS206356): 12 mL
Enzyme Solution (CS206358): 12 mL
TMB Solution (CS202682): 10 mL
Stop Solution (60193): 12 mL
Plate Sealers (CS200443): 10 Sheets
Armazenamento e estabilidade
Storage: The GFAP ELISA kit is shipped on ice and should be stored at 2-8°C upon arrival.
Stability: Kit components are stable for a minimum of 6 months from the date of receipt if stored and
handled as described above.
Stability: Kit components are stable for a minimum of 6 months from the date of receipt if stored and
handled as described above.
Informações legais
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Exoneração de responsabilidade
For research use only. Not for use in diagnostic procedures.
Palavra indicadora
Warning
Frases de perigo
Declarações de precaução
Classificações de perigo
Aquatic Chronic 2 - Eye Irrit. 2 - Met. Corr. 1 - Skin Sens. 1
Código de classe de armazenamento
8A - Combustible corrosive hazardous materials
Certificados de análise (COA)
Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica